MYC and neoplasm: Finally, we attempted to assess whether VHL loss, CDKN2A loss and MYC activation are dysregulated at tumour initiation or tumour progression, by analysing their relative frequency by TNM stage in the TCGA KIRC data set (Fig. 2g).